Efficacy and tolerability of moxifloxacin in patients with sinusitis treated in general practice - Results of a post-marketing surveillance study

被引:8
作者
Elies, W
Landen, H
Stauch, K
机构
[1] PMS Management, Bayer Hlth Care Pharma, D-51368 Leverkusen, Germany
[2] Stadt Kliniken Bielefeld gGmbH, Ohrenklin, Bielefeld, Germany
关键词
D O I
10.2165/00044011-200424080-00001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: To assess the efficacy, safety and tolerability of moxifloxacin, an 8-methoxy fluoroquinolone, in patients with respiratory tract infections (RTIs) treated in general practice in Germany. Different RTIs were analysed separately, and this paper focuses on patients with acute sinusitis. Methods, design and patients: This was an open-label, prospective, uncontrolled, post-marketing surveillance study undertaken between October 2001 and June 2002. Symptoms of sinusitis (fever, cough, nasal obstruction, nasal secretion and headache) were assessed at baseline and at follow-up visits, and classified as 'absent', 'mild' or 'severe' by the attending physician. Results: Altogether 9036 patients were treated with moxifloxacin, of whom 2405 adult men and women had sinusitis. Sinusitis symptoms were improved or cured in at least 92% of patients. Moxifloxacin produced significant improvements after only 3 days (71.6% of patients); 96.2% of patients were improved after 5 days. Most patients (89.5%) had recovered by day 8 and 97.3% by day 10. Physicians rated moxifloxacin therapy as 'good' or 'very good' in 96.6% of patients and almost all favoured prescribing moxifloxacin in the future. Very few adverse events were reported with moxifloxacin (<0.4%), and were mostly gastrointestinal disturbances. Conclusions: Moxifloxacin is a very effective and safe treatment for patients with acute sinusitis in general practice and is highly regarded by both physicians and patients because of rapid symptom improvement and good tolerability.
引用
收藏
页码:431 / 439
页数:9
相关论文
共 53 条
[1]  
[Anonymous], TODAYS THER TRENDS
[2]  
[Anonymous], 2000, J. Clin. Outcomes. Manag
[3]  
[Anonymous], EUR RESP J S36
[4]  
Balfour JAB, 2000, DRUGS, V59, P115
[5]   Acute exacerbations of chronic bronchitis - An international comparison [J].
Ball, P ;
Make, B .
CHEST, 1998, 113 (03) :199S-204S
[6]   Rapid resolution of symptoms with moxifloxacin therapy in 7223 patients with acute exacerbation of chronic bronchitis - Comparison with prior macrolide treatment [J].
Bauer, T ;
Landen, H .
CLINICAL DRUG INVESTIGATION, 2002, 22 (10) :641-651
[7]   Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin [J].
Bauernfeind, A .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (05) :639-651
[8]   Antimicrobial resistance trends in community-acquired respiratory tract pathogens in the Western Pacific Region and South Africa: report from the SENTRY antimicrobial surveillance program, (1998-1999) including an in vitro evaluation of BMS284756 [J].
Bell, JM ;
Turnidge, JD ;
Jones, RN .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2002, 19 (02) :125-132
[9]   BAY 12-8039, a novel fluoroquinolone activity against important respiratory tract pathogens [J].
Biedenbach, DJ ;
Barrett, MS ;
Croco, MAT ;
Jones, RN .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1998, 32 (01) :45-50
[10]   A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new 'respiratory quinolones' [J].
Blondeau, JM .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 :1-11